Speaker(s): 

Liping Li, MD, Resident, Geisinger - has nothing to disclose.

Valeria Moseley, MD, Resident, Geisinger - has nothing to disclose.

Moderator(s): 

Zachary Hoffer, MD, Staff Physician, Geisinger - has nothing to disclose. 

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• Describe the dynamics of mutational profiles in follicular lymphoma (FL) over time and during transformation to diffuse large B-cell lymphoma (DLBCL)
• Recognize the clinical implications of mutational evolution in FL for future therapeutic strategies
• Explain HER2 ultra-low, HER2-null, and HER2-low expression
• Analyze whether there are any differences in clinicopathological features and prognosis between HER2 ultra-low, HER2-null, and HER2-low expression

Disclosure of Relevant Financial Relationships without Commercial Interests:

The Planning Committee consisting of Zachary Hoffer, MD PhD have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose. 

Any/All relevant financial relationships have been mitigated. 

Content Disclosure:  None.

This presentation/content is HIPAA compliant. 

Commercial Support for this Session:  None.